Latest news with #ChristineBaeder
Cision Canada
27-05-2025
- Business
- Cision Canada
Apotex launches nilotinib capsules, the first generic version of Tasigna®(1) in the United States, with 180 days of exclusivity
WESTON, Fla., May 27, 2025 /CNW/ - Apotex Corp. today announced the launch of nilotinib capsules, a generic version of Tasigna®, in the United States, with 180 days of exclusivity. Nilotinib is a kinase inhibitor indicated to treat certain types of leukemia, including newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia ("Ph+ CML") in chronic phase in adults and children aged 1 year and older. It is also indicated for adults and pediatric patients with chronic or accelerated phase Ph+ CML with resistance or intolerance to prior therapy, demonstrating higher efficacy compared with other available treatments. "The launch of nilotinib highlights our commitment to providing affordable, high-quality, critical medications to patients in need," said Christine Baeder, President, Apotex USA. "By offering the first generic version of this important leukemia treatment, we improve access and outcomes for both adult and pediatric patients facing this serious disease." Please refer to the complete prescribing information, patient information leaflet, warnings and precautions, adverse reactions, and contraindications. About Apotex Apotex Corp., headquartered in Weston, Florida, is an affiliate of Apotex Inc. We improve everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic and innovative pharmaceutical and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions. Learn more about us at SOURCE Apotex Inc.
Yahoo
27-05-2025
- Business
- Yahoo
Apotex launches nilotinib capsules, the first generic version of Tasigna®(1) in the United States, with 180 days of exclusivity
WESTON, Fla., May 27, 2025 /CNW/ - Apotex Corp. today announced the launch of nilotinib capsules, a generic version of Tasigna®, in the United States, with 180 days of exclusivity. Nilotinib is a kinase inhibitor indicated to treat certain types of leukemia, including newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia ("Ph+ CML") in chronic phase in adults and children aged 1 year and older. It is also indicated for adults and pediatric patients with chronic or accelerated phase Ph+ CML with resistance or intolerance to prior therapy, demonstrating higher efficacy compared with other available treatments. "The launch of nilotinib highlights our commitment to providing affordable, high-quality, critical medications to patients in need," said Christine Baeder, President, Apotex USA. "By offering the first generic version of this important leukemia treatment, we improve access and outcomes for both adult and pediatric patients facing this serious disease." Please refer to the complete prescribing information, patient information leaflet, warnings and precautions, adverse reactions, and contraindications. About Apotex Apotex Corp., headquartered in Weston, Florida, is an affiliate of Apotex Inc. We improve everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic and innovative pharmaceutical and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions. Learn more about us at _______________________________1 Tasigna® is a registered trademark of Novartis AG View original content to download multimedia: SOURCE Apotex Inc. View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Cision Canada
09-05-2025
- Business
- Cision Canada
Apotex introduces IVRA™ (Melphalan) hydrochloride injection: First ready to dilute liquid formulation of Melphalan injection approved via 505(b)(2) NDA in the United States
WESTON, Fla., May 9, 2025 /CNW/ - Apotex Corp. today launched IVRA™ (Melphalan) hydrochloride injection 90mg/ml multidose vial ("IVRA"), first ready-to-dilute liquid formulation of Melphalan injection approved via 505(b)(2) NDA in the United States. IVRA is an alkylating drug indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate, and will be distributed primarily through hospital and institutional channels. "The launch of IVRA highlights Apotex's uncompromising dedication to access, innovation, and patient care," said Christine Baeder, President, Apotex USA. "As we introduce our novel ready-to-dilute liquid formulation of Melphalan injection approved via 505(b)(2) NDA in the United States, we reinforce our commitment to bringing much-needed products that support patients on their health journeys." Please refer to the complete prescribing information, patient information leaflet, warnings and precautions, adverse reactions, and contraindications. About Apotex Apotex Corp., headquartered in Weston, Florida, is an affiliate of Apotex Inc. We improve everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic and innovative pharmaceutical and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions. Learn more about us at SOURCE Apotex Inc.
Yahoo
13-02-2025
- Health
- Yahoo
Apotex announces grant to Healthy Mothers, Healthy Babies Coalition of Broward County to promote maternal health with $242,000 in annual funding
WESTON, Fla, Feb. 13, 2025 /PRNewswire/ - Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, today announced a grant through the Apotex Global Health Access Fund to Healthy Mothers, Healthy Babies Coalition of Broward County ("HMHB/Broward") in Lauderhill, Florida to support programs that promote maternal health and address health disparities. Building on Apotex's legacy of giving, including Apotex's global medicine donation program, the Apotex Global Health Access Fund focuses on addressing unequal access to care and low health literacy within communities where there are poor social determinants of health. Apotex's US headquarters are in Weston, Florida. HMHB/Broward is the second Apotex Global Health Access Fund grant recipient, and the first in the United States. The organization will receive $242,000 annually over the next three years to support the Mahogany Project, which provides comprehensive maternal health services to high-risk pregnant women in Broward County, aiming to improve birth outcomes and address social determinants of health. "We are thrilled to announce this Grant to Healthy Mothers, Healthy Babies, which underscores our commitment to addressing health disparities," said Christine Baeder, President of Apotex USA. "By supporting initiatives like the Mahogany Project, we aim to make a significant impact on maternal health and the well-being of families, supporting people on their health journeys." "We are incredibly grateful to Apotex for their commitment in our mission," said Dawn Liberta, Executive Director of HMHB/Broward. "This support could not have come at a better time, as it will help us expand our reach and enhance the services that we provide in helping reduce maternal and infant mortality in Broward County". In its inaugural year, the Apotex Global Health Access Fund focuses on funding maternal health programs in Canada, the United States, India, and Mexico with an annual budget of $1 million. The first grant recipient was the Rexdale Community Health Centre in Toronto. For more information about Healthy Mothers, Healthy Babies, please visit About Apotex Apotex is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for people around the world, with a broad portfolio of generic, biosimilar, and innovative branded pharmaceuticals and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions. Learn more about us at View original content to download multimedia: SOURCE Apotex Inc.
